PM 00104

Drug Profile

PM 00104

Alternative Names: PM 00104/50; PM 10450; PM00104; Zalypsis®

Latest Information Update: 22 Jun 2015

Price : $50

At a glance

  • Originator PharmaMar
  • Class Alkaloids; Antineoplastics; Small molecules
  • Mechanism of Action Cell cycle protein inhibitors; DNA binding protein modulators; Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cervical cancer; Endometrial cancer; Ewing's sarcoma; Haematological malignancies; Lymphoma; Multiple myeloma; Solid tumours; Urogenital cancer

Most Recent Events

  • 26 Feb 2015 Phase II development is still ongoing
  • 29 Nov 2012 PM 00104 is available for licensing as of 29 Nov 2012.
  • 30 Apr 2012 PharmaMar completes a phase II trial in Ewing's sarcoma in USA, France and Italy (NCT01222767)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top